Please assess the completion status of the following clinical trial:

Trial Title: CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 35 to 75 years old.~* Previous diagnosis of type 2 diabetes, fulfilling at least one of the following criteria: 1) current treatment with oral antidiabetic drugs and/or insulin; 2) a fasting glucose value above 126 mg/dl on at least 2 occasions; 3) blood glucose level at 2 hours after an oral glucose tolerance test is equal to or more than 200 mg/dl; or 4) a glycated hemoglobin (HbA1c) level \> 6.5 %~* Clinical diagnosis of mild non-proliferative diabetic retinopathy, with or without macular edema.~* Best corrected visual acuity according to ETDRS optotype from 20/40 to 20/320 letters from 4 meters (score 73-25 letters) in the studied eye.~* Spherical equivalent refraction less than ± 5 dioptre.~Exclusion Criteria:~* Prior systemic treatment for diabetic retinopathy, with the exception of nutritional supplements or vitamins.~* Pre-treatment with anti-vascular endothelial growth factor (VEGF) drugs in the studied eye. It is allowed a pre-treatment with anti-VEGF approved in the other eye more than 3 months ago.~* Prior systemic anti-VEGF, experimental or approved treatment, three months before the inclusion.~* Evidence of inflammation or infection in or around the studied eye.~* Treatment with troglitazone in the last three months.~* Eye surgery (including cataract surgery) in the studied eye three months before the inclusion.~* Late macular degeneration (geographical with foveal or neovascular involvement).~* Vascular retinal diseases, such as vascular occlusions.~* Previous diagnosis of other eye diseases that could lead to a decrease in visual acuity.~* Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mm Hg at the baseline visit.~* Stroke, transient ischemic attack, acute coronary syndrome, or hospitalization for heart failure worsening, within the previous 30 days.~* Professional drivers, risk profession or respiratory failure.~* Severe daytime sleepiness (Epworth sleepiness scale \>18)~* Concomitant treatment with high doses of acetylsalicylic acid (\> 500 mg/day) or continuous treatment with non-steroidal anti-inflammatory drugs~* Previous treatment with CPAP~* Participation in another clinical trial within the 30 days prior to randomization.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CPAP treatment (Type: EXPERIMENTAL): Diet and conventional pharmacological treatment with oral antidiabetic drugs or insulin plus continuous positive airway pressure (CPAP)
- Control treatment (Type: ACTIVE_COMPARATOR): Diet and conventional pharmacological treatment with oral antidiabetic drugs or insulin

Based on this trial design, predict the completion outcome and termination type (if applicable).